CliffBio
small molecule

DESLORATADINE

DESLORATADINE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameDESLORATADINE
Active ingredientDESLORATADINE
Strength0.5MG/ML
Dosage formSOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalMay 2016
Marketing statusRX

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.